Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-4-inducing principle of Schistosoma mansoni eggs (IPSE), also known as alpha-1, is a major immunomodulatory glycoprotein secreted by the eggs of the parasitic flatworm *Schistosoma mansoni* (and its homolog H-IPSE from *Schistosoma haematobium*). IPSE acts as an immunoglobulin-binding factor with high affinity for IgE. By binding to IgE on the surface of basophils and mast cells, it triggers the release of interleukin-4 (IL-4) and interleukin-13 (IL-13), promoting a T-helper 2 (Th2) anti-inflammatory response and the differentiation of alternatively activated (M2) macrophages. Additionally, IPSE contains a nuclear localization sequence (NLS) that allows it to function as an 'infiltrin,' translocating into host cell nuclei to modulate gene transcription. IPSE is being investigated in preclinical studies for its therapeutic potential in treating chemotherapy-induced hemorrhagic cystitis, bladder pain/hypersensitivity, bacterial urinary tract infections, type 1 diabetes, and sepsis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-4-inducing principle of Schistosoma mansoni eggs.